Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-08-10

Clinical Trial Update: Ponatinib for FLT3-ITD Acute Myelogenous Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update on ponatinib for FLT3-ITD acute myeloid leukemia, spanning Phase 1 and Phase 2, with unclear status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ponatinib (ponatinib)

Snippet

Sponsor: Versailles Hospital | Conditions: Acute Myeloid Lukemia | Phase 1, Phase 2 | Status: UNKNOWN